Royce & Associates’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Royce & Associates’s Portfolio KERX Stock Details KERX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-256,725	Closed	-$965K	–	1248
2018 Q2	$965K	Hold	256,725	–	–	0.01%	950
2018 Q1	$1.05M	Hold	256,725	–	–	0.01%	961
2017 Q4	$1.19M	Hold	256,725	–	–	0.01%	942
2017 Q3	$1.82M	Hold	256,725	–	–	0.01%	856
2017 Q2	$1.86M	Hold	256,725	–	–	0.01%	861
2017 Q1	$1.58M	Hold	256,725	–	–	0.01%	913
2016 Q4	$1.5M	Sell	256,725 -61,000	-19%	-$333K	0.01%	877
2016 Q3	$1.69M	Sell	317,725 -134,000	-30%	-$723K	0.01%	844
2016 Q2	$2.99M	Hold	451,725	–	–	0.02%	730
2016 Q1	$2.11M	Buy	451,725 +110,000	+32%	+$439K	0.01%	813
2015 Q4	$1.73M	Buy	+341,725	New	+$1.62M	0.01%	879

Other funds holding KERX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

PIMJS

PKO Investment Management Joint-Stock Warsaw, Poland $1.38B AUM 59.54% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Royce & Associates's KERX Position: Q3 2018 in Review

Royce & Associates sold out of Keryx Biopharmaceuticals Inc (KERX) in Q3 2018, closing a stake of 256,725 shares — an estimated $965K sold.

Royce & Associates first reported a position in KERX in Q4 2015 and held it in 11 quarters. The position peaked at $2.99M in Q2 2016. 123 funds tracked by Wall St. Rank hold KERX as of Q3 2018.

Royce & Associates reported no remaining Keryx Biopharmaceuticals Inc position as of Q3 2018 after selling out during the quarter.
Royce & Associates sold 256,725 Keryx Biopharmaceuticals Inc shares in Q3 2018, an estimated $965K.
Royce & Associates first reported a position in Keryx Biopharmaceuticals Inc in Q4 2015 and held it in 11 quarters.
Royce & Associates's Keryx Biopharmaceuticals Inc position peaked at $2.99M in Q2 2016.
123 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q3 2018.

Based on Royce & Associates's 13F filing for Q3 2018, filed 13 Nov 2018.